Healthcare is an exciting sector. The incredibly rapid development of effective coronavirus vaccines is just one example of its tremendous potential for innovation and making a positive social impact. We also feel there is scope for healthy returns. Healthcare companies are innovating not just in therapeutics and medical devices, but also in terms of big data and analytics. As a result, we believe we are on the verge of a transformation in how care is delivered and diseases are treated.
Speeding up drug trials
The company serves over 750 customers, including 20 of the largest pharmaceutical companies. Its technology typically accelerates regulatory submissions by 20%, which is crucial for patients likely to benefit from innovative treatments. Veeva’s platform also accelerates drug development by reducing the start-up time in clinical studies by 40%.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
A cocktail to combat Covid-19
Regeneron Pharmaceuticals (Nasdaq: REGN) is a biotechnology company engaged in the development of medicines for the treatment of serious diseases. It is pouring resources into research and development (R&D) and it maintains one of the world’s most comprehensive genetic databases, with a million people sequenced by the Regeneron Genetics Center. Regeneron is well known today for its Covid-19 antiviral drug cocktail, which has so far proved effective against the various strains of the disease, and is gaining market share from competing therapies. But Regeneron’s research effort goes far beyond Covid-19.
The company has developed and markets drugs addressing several serious medical conditions, including a type of inoperable skin cancer, wet age-related macular degeneration, asthma and eczema among others. Regeneron has approximately 30 potential treatments in clinical development.
Transforming diabetes care
DexCom (Nasdaq: DXCM) is an innovative medical-device company transforming the quality of life and standard of care for diabetics. The company produces a continuous glucose monitoring (CGM) system, which allows patients and care providers to evaluate and adjust care quickly and effectively in real time.
A sensor is placed under the patient’s skin and attached to a tiny transmitter that continuously relays data on blood-sugar levels. The data can be read on a dedicated receiver, displayed on an iPhone, or monitored remotely by a care provider. This technology is transformative: traditional glucose monitoring depends on intermittent, inconvenient and painful finger pricks and self-monitoring.
Not only is DexCom attractive for its positive impact on the lives of diabetics, but the company is also gaining market share, broadening the range of potential applications for its products and expanding geographically.
-
Reeves ‘looks at minimum UK shareholding' in ISA reformOn top of a rumoured £10,000 cash ISA limit, chancellor Rachel Reeves is reportedly considering adding a minimum UK shareholding requirement to the stocks and shares ISA
-
Rightmove: Asking prices rise by 0.3%, but increase is lower than typical for OctoberOctober saw asking prices grow by £1,165 on average, Rightmove says, but the increase is far below the usual autumn bump as the property market braces for next month’s Budget.
-
Albert Einstein's first violin sells for £860,000 at auctionAlbert Einstein left his first violin behind as he escaped Nazi Germany. Last week, it became the most expensive instrument not owned by a concert violinist
-
Who is Rob Granieri, the mysterious billionaire leader of Jane Street?Profits at Jane Street have exploded, throwing billionaire Rob Granieri into the limelight. But it’s not just the firm’s success that is prompting scrutiny
-
Emerging markets boast top-quality growth stocks at bargain pricesOpinion Lim Wen Loong, investment director at Ashoka WhiteOak Capital, selects three growth stocks where he’d put his money
-
Beware the bubble in bitcoin treasury companiesBitcoin treasury companies are no longer coining it. Short this one, says Matthew Partridge
-
Klarna leads a financial revolution – should investors buy?Klarna has ambitions to rewire the global payments system and has huge growth potential
-
New faces don’t solve old problems – why strategy also matters when it comes to investment trustsOpinion Changing managers often fails to boost a trust’s performance, says Max King
-
How to profit from silver’s record riseSilver often lets investors down, but there may now be room for further gains, says Dominic Frisby
-
Are venture-capital trusts worth investing in?Venture-capital trusts are a tax-efficient way to invest in early-stage companies. But are they worth the risk?
